Pharmacovigilance – News and Features

Using a newly discovered byproduct of dying cancer cells, University of Wisconsin–Madison researchers are developing personalized vaccines that could help keep aggressive tumors from recurring.

A new approach induces the patient’s body to produce its own CAR-T cells, relying on the same messenger RNA (mRNA) technology that was instrumental for some COVID-19 vaccines.

Researchers have discovered that the herpes virus reshapes the human genome’s architecture, rearranging its shape in three-dimensional space so that HSV-1 can access host genes most useful for its ability to reproduce.

A team of physicians from Bochum are the first to successfully use CAR T-cell therapy to treat two patients with a rare autoimmune disease of the peripheral nervous system.

A set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis have been identified by researchers at UCL and Great Ormond Street Hospital for Children.

New research has revealed that a type of drug commonly used to treat heart disease, asthma and thrombosis, also stimulates bone growth – suggesting that these drugs could be repurposed for treating skeletal growth disorders.

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1.

Two existing medications commonly used for combating smoking and depression can be used together to effectively treat alcohol use disorder, a new study suggests. The two drugs also lessen the risk for nausea and alcohol cravings.

Researchers at Michigan Medicine uncovered a key mechanism that regulates blood pressure and vascular remodeling — increasing downstream risk of heart attack and stroke — in people with a genetic variant linked to high blood pressure.

Two key protein structures in the body are being visualized for the first time, thanks in part to the latest technology — potentially opening the door for better-designed therapeutics.